Real-world outcomes of subcutaneous infliximab in a Middle Eastern inflammatory bowel disease cohort: a prospective study of switch and de novo treatment strategies.

Crohns Colitis 360 · 2026 · PMC13371750 · PMID 42459865

Europe PMC DOI

hedged sentence

0.0820

closest p · 1.6× alpha

0.0820

boldest claim

The sentences

near-significantP = .082so close (0.05 < p ≤ 0.1)

Our exploratory analysis revealed a near-significant inverse correlation between BMI and SC infliximab trough levels ( P = .082), and a stepwise decrease in median trough levels across BMI categories was observed: 29.0 (20.0, 45.0) mcg/mL in normal weight patients, 23.0 (10.4, 40.0) mcg/mL in overweight patients, and 20.0 (12.0, 39.0) mcg/mL in obese patients, though this did not reach statistical significance.

also in 1,650 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.